email article
The migraine prevention drug erenumab (Aimovig) was associated with elevated blood pressure (BP), an FDA analysis of postmarketing case reports suggested.
Of 61 erenumab-linked hypertension cases submitted to the FDA Adverse Event Reporting System (FAERS), 41 were associated with a serious outcome according to regulatory criteria, including seven cases that specified hospitalization, reported Suprat Saely, PharmD, of the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland, and colleagues.
About half of the 61 cases reported baseline measurements. In those patients, median systolic BP increase was 39 mm Hg and median diastolic BP increase was 28 mm Hg. The temporal association observed in our case series suggests that erenumab can cause markedly elevated blood pressure with or without pre-existing hypertension, Saely and colleagues wrote in